Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

Joseph, Alain; Cloutier, Martin; Guérin, Annie; Nitulescu, Roy; Sikirica, Vanja

doi:10.2147/ppa.s98498

Cited by 4 publications

(5 citation statements)

References 51 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an earlier (United States) study, the rate of discontinuation in adults was within the range observed in the present study, despite a shorter study duration (1 year). Discontinuation of LDX in the present study was somewhat lower than that reported for ATX ( Joseph et al 2016), whereas in another 1-year (United States) study, discontinuation of MPH in children was within the range seen in the present study (Faraone et al 2007).…”

Section: Discussioncontrasting

confidence: 58%

“…In a recent 3-year study in adults in France, the calculated average daily dose of MPH exceeded the maximum approved dose according to European labels (Pauly et al 2018). Two United States studies have shown that the calculated daily average consumption, relative to the prescribed dose, is generally lower for LDX than for OROS-MPH, MAS XR, or ATX (Hodgkins et al 2012 ; Joseph et al 2016 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe

Siffel

Page

Maxwell

et al. 2020

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

Objectives: Lisdexamfetamine dimesylate (LDX) is approved in some European countries for the second-line treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents when response to previous methylphenidate (MPH) treatment is considered clinically inadequate, and as a first-line treatment in adults. Limited evidence exists on the real-world use of LDX across Europe. This retrospective study evaluated LDX drug utilization patterns from eight European countries for up to 5 years. Methods: Data were collected from national registries (Denmark, Finland, Norway, Sweden), electronic medical records (Germany, Spain, United Kingdom), and prescription databases (Switzerland) in eight European countries. Patients were included if they were prescribed LDX at least once since the LDX launch date in each country. Demographic and clinical characteristics, and LDX prescription data included patient age and gender, a recorded diagnosis of ADHD, the number of prescriptions per participant, previous MPH prescription recorded, average daily dose, treatment persistence, discontinuation, and switching of medications. Results: Overall, information for 59,292 patients (437,272 LDX prescriptions) was analyzed. Most patients were male (58.1%-84.3%) and fewer than 1% were under 6 years of age. Extensive use of LDX in adults was observed in four countries (Denmark, Finland, Norway, and Sweden), including countries where LDX was not approved for this age group. Most patients had a recorded diagnosis of ADHD (61.9%-95.4%). The mean number of prescriptions per patient ranged from 5.4 to 10.0. At least 79.6% of patients with ADHD had a recorded previous MPH prescription. Mean duration of LDX exposure ranged from 233.1 to 410.8 days. The average daily dose of LDX was £70 mg/day for most patients (79.4%-99.7%). The 5year discontinuation rate ranged from 22.8% to 70.6% and was below 40% for most countries. The proportion of patients switching from LDX to other medications was £33.8. Conclusions: This study provides the first long-term, real-world information related to LDX use by children, adolescents, and adults in Europe in the 5 years since its first launch in the region. Most LDX prescriptions fulfilled label requirements regarding a recorded diagnosis of ADHD before treatment initiation, previous MPH use, and an average daily dose of £70 mg/day. LDX was largely prescribed within the indicated age range, although adult use of LDX was high in some countries where LDX is not approved for this population.

show abstract

Section: Discussioncontrasting

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe

Siffel

Page

Maxwell

et al. 2020

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…A study using US commercial claims databases compared 3,392 patients who discontinued methylphenidate and started either lisdexamfetamine or atomoxetine as second-line treatments. The study found that patients treated with lisdexamfetamine had higher treatment adherence and lower discontinuation rates as compared to those treated with atomoxetine [ 15 ].…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that due to its pharmacokinetic profile, lisdexamfetamine has a lower abuse-related drug-liking score compared to immediate-release dextroamphetamine [ 17 ]. In addition, various studies have demonstrated the efficacy of lisdexamfetamine in the treatment of adults with ADHD [ 14 , 15 , 18 ]. Additionally, lisdexamfetamine may be effective in the treatment of stimulant (methamphetamine) use disorder [ 4 , 19 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder

Levine,

Swanson

2023

Case Reports in Psychiatry

View full text Add to dashboard Cite

Introduction. The treatment of attention deficit hyperactivity disorder (ADHD) with stimulants among patients with stimulant use disorder carries concern for efficacy and exacerbation of addictive behaviors. Lisdexamfetamine is a unique stimulant used to treat ADHD with a lower abuse potential compared to other stimulants, as the medication is the only prodrug in its class. To our knowledge, there are no reports in the literature of the use of lisdexamfetamine to treat ADHD in patients with stimulant use disorder. Methods. We present a 33-year-old male with a history of stimulant (methamphetamine) use disorder, who was found to have long-standing ADHD. The patient was treated with lisdexamfetamine 30 mg, which was increased and sustained at 40 mg. Results. The patient reported significant improvement in focus, concentration, calmness, organization of thoughts, and less of a tendency to procrastinate. Additionally, he denied exacerbation of anxiety or sleep disturbances. He reported his cravings for stimulants were significantly decreased. After 2 months of treatment, he had moved out from his sober living facility, started a new job, and gained a promotion. He had no use of illicit substances, which was proven by routine urine drug screens. Conclusion. Our patient’s ADHD was successfully treated with lisdexamfetamine. Not only did the patient’s ADHD symptoms improve, but his cravings for stimulants were relieved. ADHD is common among patients with stimulant use disorder. Patients with ADHD and stimulant use disorder should not necessarily forgo pharmacologic treatment with stimulants for concerns of abuse. Due to its unique pharmacokinetic profile, lisdexamfetamine is a feasible treatment for patients with ADHD and a history of stimulant use disorder.

show abstract

“…La alta y prolongada eficacia, medida a través de parámetros clínicos de síntomas cardinales del TDAH, de afectación del funcionamiento cotidiano, calidad de vida y neuropsicológicos, así como la facilidad de administración y, por tanto, la adhesión terapéutica, el rápido comienzo de acción y el buen perfil de seguridad, configuran la LDX como un tratamiento completo y efectivo [7,19,21,39], con una satisfactoria relación coste-efectividad [27,44,45].…”

Section: Acción Efectiva Aproximadaunclassified

Actualización en el tratamiento farmacológico del trastorno por déficit de atención/hiperactividad: lisdexanfetamina y guanfacina de liberación retardada

Fernández-Mayoralas¹,

Perrone²,

Jareño³

et al. 2017

RevNeurol

View full text Add to dashboard Cite

show abstract

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine

Cited by 4 publications

References 51 publications

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe

The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder

Actualización en el tratamiento farmacológico del trastorno por déficit de atención/hiperactividad: lisdexanfetamina y guanfacina de liberación retardada

Contact Info

Product

Resources

About